3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
4
Breast
3
Genitourinary
2
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Classical hematology
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Filgrastim
14
Cyclophosphamide
13
Carboplatin
12
Paclitaxel
8
Ifosfamide
8
Doxorubicin
8
pembrolizumab
7
Peripheral Blood Stem Cell Transplantation
6
Gemcitabine
6
fludarabine
5
Temozolomide
5
Specimen Handling
5
Radiotherapy
5
Cisplatin
5
Magnetic Resonance Spectroscopy
4
Etoposide
4
Docetaxel
4
Amifostine
4
aldesleukin
3
Trastuzumab
3
Taxes
3
Psychiatric Rehabilitation
3
Melphalan
3
Fulvestrant
3
Bevacizumab
3
sodium thiosulfate
2
pazopanib
2
pamiparib
2
palbociclib
2
etoposide phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Genetic Counseling
×
Sarcoma
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled